In a nutshell This study looked at whether iGlarLixi (Soliqua), a combination of long-acting insulin glargine (Lantus) and lixisenatide (Lyxumia), can improve glucose control for patients with type 2 diabetes (T2D) uncontrolled with long-acting insulin alone. It found that iGlarLixi improved overall and after-meal blood sugar control compared to insulin...
Read More
In a nutshell This article compared the safety and effectiveness of insulin glargine (Lantus) at two different doses in the management of type 1 diabetes (T1D). The authors concluded that the effectiveness and safety of both doses were similar. Some background In T1D the body does not make insulin and cannot lower the blood...
Read MoreIn a nutshell This study is examining the safety and effectiveness of a new insulin plan for people with type 2 diabetes (T2D) that are already being treated with basal insulin. The new insulin being evaluated is a once-a-week administration of insulin instead of daily injections of basal insulin, which should be substantially more convenient for...
Read More
In a nutshell This study looked at the effects of IDegLira, a combination insulin drug, on outcomes in patients with uncontrolled type 2 diabetes. They found that IDegLira improved glycemic (blood sugar) control and aided weight loss in these patients. Some background The treatment of type 2 diabetes is to achieve glycemic control. This can slow...
Read More
In a nutshell This study investigated the effect of continuous glucose monitoring (CGM) in managing blood sugar levels in patients with type 1 diabetes treated with multiple daily insulin injections. They found CGM resulted in a clinically meaningful improvement in glycemic (blood sugar) control. Some background Glycemic control is critical for...
Read MoreIn a nutshell This study examined the variability of insulin degludec and insulin glargine in reducing blood glucose levels. Some background Patients with type1 diabetes (T1D) must inject rapid-acting insulin and long-acting insulin each day. Insulin glargine (Lantus) is a long-acting insulin injected once daily. It slowly reduces blood glucose...
Read MoreIn a nutshell In this study researchers examined two types of insulin; insulin degludec (triseba; IDeg) and insulin glargine (lantus; IGlar). This study compared the quality of life (QOL) as reported by patients between users of these two drugs. Some background Insulin is often used to manage blood sugar levels in diabetic patients. However,...
Read More
